Expressed on AML LSCs, particularly in MLL-rearranged AML, where it promotes proliferation. Preclinical antibody blockade reduces AML progression. Also expressed on endothelial cells and some myeloid progenitors, which may restrict specificity and therapeutic applicability. Here, KMT2A is linked to acute myeloid leukemia.